| AstraZeneca PLC | Precision Medicine Platforms | $285.2b | $188.03 | +0.0% | 1.7M | |
| Thermo Fisher Scientific, Inc. | Precision Medicine Platforms | $258.7b | $695.00 | +0.1% | 1.5M | |
| Danaher Corporation | Precision Medicine Platforms | $161.8b | $231.12 | +0.4% | 2.5M | |
| Vertex Pharmaceuticals Inc | Gene Therapy & Gene Editing | $134.5b | $535.84 | -0.8% | 487.1K | |
| Regeneron Pharmaceuticals Inc | Gene Therapy & Gene Editing | $100.7b | $957.03 | +0.5% | 476.6K | |
| Natera, Inc. Common Stock | Genetic Testing & Diagnostics | $56.0b | $318.40 | -1.1% | 1.2M | |
| Waters Corp | Precision Medicine Platforms | $45.2b | $456.99 | -0.4% | 437.0K | |
| Illumina Inc | Genetic Testing & Diagnostics | $36.0b | $207.76 | -1.2% | 938.2K | |
| Labcorp Holdings Inc. | Genetic Testing & Diagnostics | $28.7b | $370.36 | -0.5% | 358.2K | |
| Guardant Health, Inc. Common Stock | Precision Medicine Platforms | $23.5b | $148.16 | -2.0% | 1.1M | |
| Insmed, Inc. | Gene Therapy & Gene Editing | $22.9b | $120.39 | +2.6% | 1.1M | |
| Alnylam Pharmaceuticals, Inc. | RNA Therapeutics | $21.4b | $165.35 | +5.3% | 3.0M | |
| Revvity, Inc. | Precision Medicine Platforms | $18.2b | $154.72 | -1.7% | 1.1M | |
| BridgeBio Pharma, Inc. Common Stock | Precision Medicine Platforms | $14.4b | $78.30 | +0.1% | 864.1K | |
| Tempus AI, Inc. Class A Common Stock | Precision Medicine Platforms | $14.2b | $70.24 | -5.7% | 4.9M | |
| Bio-Techne Corp. | Precision Medicine Platforms | $11.4b | $72.63 | -0.1% | 1.9M | |
| Kymera Therapeutics, Inc. Common Stock | Precision Medicine Platforms | $10.8b | $127.61 | +0.4% | 629.5K | |
| BioMarin Pharmaceuticals Inc | Gene Therapy & Gene Editing | $10.8b | $57.24 | +0.9% | 875.0K | |
| QIAGEN N.V. | Genetic Testing & Diagnostics | $10.4b | $49.90 | -0.4% | 1.5M | |
| Bio-Rad Laboratories, Inc.Class A | Genetic Testing & Diagnostics | $10.0b | $366.26 | -1.1% | 218.0K | |
| Nuvalent, Inc. Class A Common Stock | Precision Medicine Platforms | $9.8b | $123.96 | 0.0% | N/A | |
| Twist Bioscience Corporation Common Stock | Precision Medicine Platforms | $9.3b | $110.20 | -2.3% | 1.9M | |
| Caris Life Sciences, Inc. Common Stock | Precision Medicine Platforms | $9.3b | $23.40 | -3.9% | 2.6M | |
| Krystal Biotech, Inc. Common Stock | Gene Therapy & Gene Editing | $9.0b | $307.50 | -0.2% | 79.1K | |
| 10x Genomics, Inc. Class A Common Stock | Genetic Testing & Diagnostics | $8.5b | $57.56 | -1.6% | 1.8M | |
| Arrowhead Research Corporation | RNA Therapeutics | $8.4b | $47.63 | +1.3% | 2.7M | |
| Praxis Precision Medicines, Inc. Common Stock | Precision Medicine Platforms | $7.8b | $322.59 | +1.0% | 289.9K | |
| Ionis Pharmaceuticals, Inc. Common Stock | RNA Therapeutics | $6.7b | $28.92 | +6.4% | 4.7M | |
| Lantheus Holdings, Inc | Precision Medicine Platforms | $6.6b | $101.59 | +0.3% | 614.2K | |
| BillionToOne, Inc. Class A Common Stock | Genetic Testing & Diagnostics | $5.2b | $108.75 | -5.0% | 609.2K | |
| CRISPR Therapeutics AG | Gene Therapy & Gene Editing | $4.8b | $42.33 | -0.9% | 1.6M | |
| CareDx, Inc. | Genetic Testing & DiagnosticsPrecision Medicine Platforms | $4.6b | $78.26 | -2.4% | 641.1K | |
| Amicus Therapeutics, Inc | Gene Therapy & Gene Editing | $4.5b | $14.49 | +0.0% | 3.5M | |
| Adaptive Biotechnologies Corporation Common Stock | Precision Medicine Platforms | $4.1b | $29.05 | -1.4% | 1.4M | |
| Veracyte, Inc. | Genetic Testing & Diagnostics | $4.0b | $23.71 | -1.3% | 1.6M | |
| Dyne Therapeutics, Inc. Common Stock | Precision Medicine Platforms | $3.4b | $17.16 | +0.9% | 1.4M | |
| IDEAYA Biosciences, Inc. Common Stock | Precision Medicine Platforms | $3.0b | $32.19 | +1.0% | 648.5K | |
| Beam Therapeutics Inc. Common Stock | Gene Therapy & Gene Editing | $2.7b | $23.05 | -5.0% | 1.8M | |
| NeoGenomics, Inc. | Genetic Testing & Diagnostics | $2.2b | $16.02 | -3.2% | 1.9M | |
| Alamar Biosciences, Inc. Common Stock | Precision Medicine Platforms | $2.1b | $30.77 | -2.9% | 592.0K | |
| Vericel Corporation | Gene Therapy & Gene Editing | $2.1b | $56.95 | -0.9% | 490.4K | |
| GeneDx Holdings Corp. Class A Common Stock | Precision Medicine PlatformsGenetic Testing & Diagnostics | $2.0b | $52.41 | +0.9% | 1.0M | |
| Sarepta Therapeutics,, Inc. Common Stock | Gene Therapy & Gene Editing | $2.0b | $15.85 | +0.4% | 1.1M | |
| Precigen, Inc. Common Stock | Gene Therapy & Gene Editing | $1.9b | $4.51 | -3.0% | 3.1M | |
| BioLife Solutions Inc. | Gene Therapy & Gene Editing | $1.8b | $38.60 | 0.0% | N/A | |
| Maze Therapeutics, Inc. Common Stock | Precision Medicine Platforms | $1.8b | $34.26 | -5.0% | 1.3M | |
| Personalis, Inc. Common Stock | Genetic Testing & Diagnostics | $1.7b | $15.71 | -1.0% | 2.5M | |
| Intellia Therapeutics, Inc | Gene Therapy & Gene Editing | $1.7b | $9.81 | -8.0% | 8.8M | |
| uniQure N.V. | Gene Therapy & Gene Editing | $1.7b | $24.05 | -3.2% | 1.3M | |
| Azenta, Inc. | Genetic Testing & Diagnostics | $1.6b | $45.62 | +4.1% | 770.0K |